An Open-Label Non-Randomized, Multi-Center Phase-2 Study of Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma
Phase of Trial: Phase II
Latest Information Update: 27 Mar 2018
At a glance
- Drugs MDNA 55 (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- Sponsors Medicenna Therapeutics
- 12 Feb 2018 According to a Medicenna Therapeutics media release, enrolment is expected to be completed by by mid-2018.
- 21 Dec 2017 Planned End Date changed from 1 Dec 2018 to 1 Jul 2018.
- 21 Dec 2017 Planned primary completion date changed from 1 Nov 2018 to 1 Jun 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History